Integrity Solutions

OCTOBER 23, 2023

One of the most common pathways into sales is… accidental. Many people find themselves taking a sales role almost as a layover en route to their “real” career. It’s the thing to do while they figure out what it is they actually want to do. And then a funny thing happens: They realize they like doing sales. Along the way, though, they often discover that there are many intangibles and unwritten rules of sales that are a huge factor in getting established and then to the ne

Sales 109

Sales Networking Prospecting Education 109

MedCity News

OCTOBER 24, 2023

The future of pharmaceutical innovation hinges on enhanced data discovery and collaboration. Through data sharing and collective effort, the pharmaceutical industry can accelerate the development of new therapies.

Pharma 126

Pharma Pharmaceutical Biopharma 126

Fierce Pharma

OCTOBER 30, 2023

Editor's note: This story has been updated with a comment from Pfizer. An earlier version of the story stated that nearly 800 jobs would be affected. | After plunging COVID revenues prompted Pfizer to embark on a cost-cutting crusade, more details about the company's savings efforts are coming into focus.

359

359

PharmaVoice

OCTOBER 19, 2023

The actor of “Heroes” and “Star Wars: The Force Awakens” fame is starring in another role as a patient advocate for people with epilepsy.

Patients 138

Patients 138

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

Pharmaceutical Commerce

OCTOBER 5, 2023

In an interview at LogiPharma USA 2023 with Pharma Commerce Editor Nicholas Saraceno, Tracy Nasarenko, Sr. Director of Community Engagement for Pharmaceuticals, GS1 US highlights her “DSCSA—Final Checks to Have Before Deadlines.

Pharma 124

Pharma Pharmaceutical 124

European Pharmaceutical Review

OCTOBER 10, 2023

Schneider Electric, a leader in digital transformation, energy management and automation, has announced the speaker lineup for its exclusive event, Life Sciences Innovation Day – Accelerating Digital Transformation Ambition. Set at the world-renowned Silverstone F1 Racetrack on 18 October 2023, it promises to be a day of immersive insights and top rate networking.

Engineering 123

Engineering Networking Manufacturing Consulting 123

MedCity News

OCTOBER 1, 2023

It’s critical that we address these examples of institutionalized bias and racism in how we approach clinical trials for drugs and devices. While it’s a daunting task, the path forward is surprisingly clear, and AI can be instrumental in the next step of overcoming unconscious biases inherent in clinical trial processes.

Biopharma 133

Biopharma 133

Fierce Pharma

OCTOBER 16, 2023

As the coronavirus outbreak has shifted to the endemic phase, drugmakers have warned of a drop in demand for COVID-19 products, with the impact coming into focus during the fall vaccination season. | Pfizer has slashed its 2023 revenue projection by $9 billion because of declining demand for COVID products. The company now expects sales to reach between $58 billion and $61 billion, down from a prior range of $67 billion to $70 billion.

Sales 363

Sales 363

PharmaVoice

OCTOBER 25, 2023

“They have the money,” and they’re using it to influence drug development, according to the executive director of the IQVIA Institute for Human Data Science.

Patients 128

Patients 128

PharmExec

OCTOBER 13, 2023

Industry experts discuss the relationship between digital and traditional (key) opinion leaders and how companies are adjusting their strategies to harness the unique brand engagement benefits each role can provide in driving better patient outcomes.

Pharma 119

Pharma Patients 119

Advertisement

European Pharmaceutical Review

OCTOBER 18, 2023

The US Food and Drug Administration (FDA) has approved XPHOZAH ® (tenapanor), the first and only phosphate absorption inhibitor. Ardelyx’s first-in-class oral treatment is indicated to reduce serum phosphorus in adults with chronic kidney disease ( CKD ) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant to phosphate binder therapy.

Food and Drug Administration 119

Food and Drug Administration FDA Food Patients 119

Copyright Clearance Center

OCTOBER 10, 2023

October 10, 2023 – Danvers, Mass. – CCC , the leading provider of Open Access (OA) workflow solutions, announces new data import capabilities and AI-enabled affiliation matching in its OA Agreement Intelligence modeling and analytics tool that provides publishers with a 360-degree view of disambiguated publication data to build accurate, transparent institutional offers regarding OA.

Training 119

Training Government Management Leads 119

MedCity News

OCTOBER 15, 2023

The FDA’s digital health advisory committee will discuss technologies such as artificial intelligence and machine learning, virtual reality, and digital therapeutics as well as topics like decentralized clinical trials and patient-generated health data. Committee member nominations are due in December.

FDA 132

FDA Patients Biopharma 132

Fierce Pharma

OCTOBER 16, 2023

Up until this point, immune checkpoint inhibitors have been allowed to treat early-stage non-small cell lung cancer (NSCLC) either before or after surgery. | Thanks to a new FDA approval for Merck's Keytruda, a continuous immunotherapy regimen around surgery is now available for patients with early-stage non-small cell lung cancer. The drug's label already includes an overall survival win from a key trial.

FDA 348

FDA Patients 348

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

PharmaVoice

OCTOBER 17, 2023

Phenylephrine’s future is up in the air with an FDA committee saying it’s not effective and a class action lawsuit alleging false advertising. What comes next could have big repercussions.

FDA 119

FDA Medicine 119

Healthcare Success

OCTOBER 30, 2023

Do you want to compete in each of your local markets? Do you want to position your healthcare products and services where your target audience actively seeks them? If so, you need a custom digital marketing strategy and budget for each location. We like to call this budget the “minimum daily requirement.” Why is this so important? Unless you have a solid local strategy, your business will not show up online where and when it matters most.

Marketing 116

Marketing Healthcare Healthcare Media 116

European Pharmaceutical Review

OCTOBER 24, 2023

Europe’s pharmaceutical packaging and labelling market is projected to reach $35.78 billion in 2028, according to a report by Arizton. Having been valued at $27.04 billion in 2022, the pharmaceutical packaging and labelling market in Europe is expected to expand at a compound annual growth rate (CAGR) of 4.78 percent up to 2028. Europe’s position in the global pharmaceutical packaging and labelling market The authors highlighted that Europe led the worldwide market at 27 percent in 2022.

Pharmaceutical 118

Pharmaceutical Marketing Medicine Pharmaceutical Sales 118

Copyright Clearance Center

OCTOBER 3, 2023

October 3, 2023 – Danvers, Mass. – CCC , a pioneer in voluntary collective licensing and leading information solutions provider to organizations around the world, will host a Town Hall via LinkedIn Live on “AI, Licensing, and the Path Forward” on Thursday, 12 October, 10:00 EDT/15:00 BST/16:00 CEST. CCC’s Vice President, General Counsel Catherine Zaller Rowland and a panel of legal experts including Prof.

Training 119

Training Media Leads Marketing 119

Advertiser: ZoomInfo

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

Competition

MedCity News

OCTOBER 11, 2023

Enrollment in Medicare Advantage is increasing, but the program has been drawing scrutiny from the government. Can the program be saved? One expert believes Medicare Advantage is a failed experiment. Another thinks that while the program has its flaws, it shows tremendous potential.

Government 131

Government 131

Fierce Pharma

OCTOBER 9, 2023

Following similar initiatives to bolster mRNA vaccine production and access in Africa, the Bill & Melinda Gates Foundation is providing new funding to a clutch of drugmakers. | Following similar initiatives to bolster mRNA vaccine production and access in Africa, the Bill & Melinda Gates Foundation is providing new funding to a clutch of drugmakers.

343

343

PM360

OCTOBER 25, 2023

Everyone’s buzzing about generative artificial intelligence (AI), and it’s true that technology like ChatGPT is already having an enormous impact on advertising and marketing. But other AI tools that our industry has been using for years have changed the face of media planning and buying. The examples below share how we have been utilizing AI for our pharma clients.

Media 115

Media Marketing Education Training 115

Pharmaceutical Technology

OCTOBER 18, 2023

The FDA approved Hyloris’s non-opioid painkiller as the agency increases efforts to mitigate an opioid crisis.

FDA 145

FDA 145

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

European Pharmaceutical Review

OCTOBER 20, 2023

A paper by Tim Sandle, Head of Microbiology, Risk Management and Sterility Assurance at Bio Products Laboratory Ltd has underlined the importance of proper cleanroom disinfection practices by elucidating on the robust survival mechanism of the bacterium Micrococcus luteus (M. luteus). As “one of the most abundant organisms on the outer layer of human skin” M. luteus is a common contaminant recovered from cleanrooms, according to Sandle.

Pharmaceutical 116

Pharmaceutical Management 116

Copyright Clearance Center

OCTOBER 31, 2023

Oct. 31, 2023 – Danvers, Mass. – CCC , a pioneer in voluntary collective licensing and leading information solutions provider, held its annual ‘We Not Me’ global volunteering event as part of a year-round charity initiative about demonstrating the power of individual action to build community and support the common good. CCC US-based staff collaborated with colleagues in various parts of the country including Massachusetts, New Hampshire, Rhode Island, Oregon, Washington, and California, serving

Education 115

Education Leads 115

MedCity News

OCTOBER 16, 2023

At HLTH, Mayo Clinic Platform President John Halamka gave a window into how his health system is mitigating generative AI risks. Some of the measures Mayo is taking include running analyses on how well algorithms perform across various subgroups and training models only on internal de-identified data.

Training 130

Training Healthcare Healthcare 130

Fierce Pharma

OCTOBER 31, 2023

For Pfizer, several years of pandemic megaprofits have soured as overstocked COVID-19 drugs and vaccines take a major toll on the drug behemoth’s financials. | Pfizer's pandemic megaprofits have soured as overstocked COVID-19 drugs and vaccines take a major toll on the drug behemoth’s financials.

Sales 338

Sales 338

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales

PM360

OCTOBER 25, 2023

When it comes to healthcare decisions, patients are not the only ones calling the shots. Shared decision-making is a process where multiple parties work together to make decisions on testing, treatments, and care plans, among other things. This relationship between the patient and their provider is the backbone of modern healthcare, but we often overlook influential and extremely common stakeholders that medical brands sometimes miss: the patient’s family.

Healthcare 111

Healthcare Healthcare Patients Physicians 111

Pharmaceutical Technology

OCTOBER 17, 2023

In October 2023, Novo Nordisk announced that its trial studying Ozempic (semaglutide) in diabetic CKD patients, will come to a halt almost a year prior to its planned completion.

Patients 111

Patients 111

European Pharmaceutical Review

OCTOBER 30, 2023

Echoes of the global health challenges we faced during the COVID-19 pandemic still linger as new variants emerge and COVID continues to make headlines. A question that continues to sit in the back of many people’s minds is what happens if there is another outbreak or global pandemic? Are we preparing and how ready are we for the next one? Vaccitech’s Chief Business Officer, Graham Griffiths, discusses key learnings in drug and vaccine development , the challenges of preparing for the unknown, an

Distribution 114

Distribution Manufacturing Pharmaceutical Government 114

PharmaVoice

OCTOBER 4, 2023

The FDA wouldn’t review a drug that was 90% effective. In rare diseases, this is too common, said the UltraGenyx CEO and a leading rare disease researcher.

FDA 111

FDA Leads 111

Advertisement

Distribution